

Radiotherapy Board

Summary Report 7: October 2025

The [Radiotherapy Board](#) is a partnership between the Institute of Physics and Engineering in Medicine, The Royal College of Radiologists and the Society and College of Radiographers. It provides guidance, oversight and support for the continuing development of high-quality radiotherapy services for UK patients with cancer.

The Board's three strategic priorities are:

- **Workforce** advising stakeholders and policy-makers about future workforce requirements, to ensure a trained, skilled and flexible, multi-disciplinary radiotherapy workforce
- **Guidance** providing professional guidance to underpin the highest standards of radiotherapy service delivery
- **Equipment** promoting the need for sufficient radiotherapy equipment to meet increasing patient demand and provide a high-quality service.

During the last six months (April-October 2025) the Board's major achievement was:

- **Launching the [green Radiotherapy Framework](#) (gRTF)**

This new scheme sets out actions that healthcare professionals in radiotherapy can take to contribute to the NHS response to climate change and enables radiotherapy departments to apply for an Award to indicate their current level of sustainable working. The gRTF was launched in summer 2025.

The Board's ongoing work programme includes:

- **preparing new guidance on managing patients with non-cardiac active implantable medical devices (AIMDs)**

The aim of this guidance is to provide practical, evidence-informed recommendations for radiotherapy centres that will support safe and effective treatment planning and delivery for patients with non-cardiac AIMDs, and encourage consistent multi-disciplinary approaches and patient-centred care. A first draft has been produced and the Board is aiming to publish this guidance by spring 2026.

- **reviewing and updating its guidance entitled *Ionising Radiation (Medical Exposure) Regulations: implications for clinical practice in radiotherapy***

This review will ensure that the existing guidance, published in 2020, reflects the changes in education, training, clinical practice and governance introduced by the IR(ME)R (Amendment) Regulations 2024. It is being undertaken in association with the UK Health Security Agency and will incorporate additional advice published by the Radiotherapy Board in 2023 on the training records needed by clinical oncologists to support their roles as operators and practitioners under the IR(ME)R.

- **investigating the provision of services for patients experiencing ongoing consequences ('late effects') from their radiotherapy treatment**

A short survey has been prepared to collect baseline information from all centres about radiotherapy late effects services in the UK. The results will help to inform the possible future development of national guidance in this area.

There is more information about the work of the Radiotherapy Board on [these web pages](#) (hosted for the Board by the RCR) and you can contact us at RadiotherapyBoard@rcr.ac.uk.